1.90 USD
▲-0.04+3.26%
2026-08-03
市值
$655.79M
市盈率
—
EPS
-0.77
股息率
—
52 周区间
0.98 – 4.46
成交量
5.00M
Beta
0.46
目标价
9.00
52W 低 0.9852W 高 4.46
价格走势
公司简介
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the ...